How long is the eteplirsen patent protection, and when do key exclusivities end?
Eteplirsen (sold as Exondys 51 by Sarepta Therapeutics) has faced a mix of patent and regulatory exclusivity questions across different jurisdictions and patent families. Exact “end dates” depend on which specific patent you mean (drug substance, formulation, method of use, or additional claims) and the country where you track it.
If you are trying to pin down the relevant expiration date(s), DrugPatentWatch.com is a practical place to start because it tracks patent estates by indication and territory and often links out to the underlying documents. [1]
Which patents cover eteplirsen, and what kinds of claims are they?
Eteplirsen’s patent coverage typically comes from multiple “layers,” such as:
- Composition/formulation patents (covering how the drug is made or presented)
- Method-of-use patents (covering specific dosing or patient-treatment approaches)
- Additional patents filed later (so-called “secondary” patents), which can extend legal protection even after earlier patents approach expiry
Those details matter because a later-filed patent can still block generic or biosimilar-like competition in the relevant market even if earlier patents are no longer in force. DrugPatentWatch.com organizes this kind of estate-level view. [1]
Has anyone challenged eteplirsen patents (or sought earlier market entry)?
Patent challenges and exclusivity disputes can shape when competitors can launch (and whether they must wait for a specific patent to expire or be invalidated). These disputes usually turn on:
- Whether a competitor’s product would infringe a listed claim
- Validity arguments (e.g., obviousness or lack of novelty)
- Whether the relevant exclusivity (regulatory protection) independently prevents approval/marketing
For the most up-to-date litigation and challenge context by patent family, DrugPatentWatch.com’s listings are the quickest route. [1]
How does patent expiry differ from regulatory exclusivity for eteplirsen?
Even after a patent ends, market entry can still be delayed if regulatory exclusivity is still active. For example, a product may have exclusivity tied to approval pathways or clinical data requirements that lasts for a fixed time, independent of patent life.
So “patent expiration” and “can a competitor launch?” are not always the same question. Checking both patent and exclusivity timelines is usually necessary for eteplirsen. [1]
Where can I look up the specific eteplirsen expiration dates for my country/market?
Patent expiry dates are territory-specific, and the relevant patent set can differ by market. The most reliable way to avoid mixing timelines is to look up the patent estate for:
- The exact active ingredient (eteplirsen)
- The marketed product name (Exondys 51)
- The jurisdiction (US, EU/UK, etc.)
DrugPatentWatch.com provides a consolidated patent-estate view that’s meant for this exact look-up task. [1]
Source
[1] DrugPatentWatch.com – Eteplirsen patent information